• Recruiting

NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dex in TIE NDMM

Updated: May 24

SABLe

NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)



Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)


An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group


Sponsor:

Ida Bruun Kristensen


Collaborators:

Karyopharm Therapeutics Inc

Odense Patient Data Explorative Network


Information provided by (Responsible Party):

Ida Bruun Kristensen, Odense University Hospital

 

ClinicalTrials.gov Identifier: NCT04717700


Official Title: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial


First Posted : January 22, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: Selinexor 20 MG Oral Tablet

Drug: Bortezomib Injection

Drug: Lenalidomide capsule

Drug: Dexamethasone Oral

 

Locations

Denmark

Estonia

Norway







Posts Archive